ALLMedicine™ Essential Thrombocytosis Center
Research & Reviews 90 results
https://doi.org/10.1111/bjh.18650
British Journal of Haematology; Harris Z, Kaizer H et. al.
Jan 18th, 2023 - The aim of this study was to compare the genomic features and clinical outcomes between paediatric and young adult patients (PAYA, <40 years) and older adults (OA, ≥40 years) with myeloproliferative neoplasms (MPN) to gain insight into pathogenesi...
http://emedicine.medscape.com/article/206811-overview
Aug 10th, 2022 - Practice Essentials Platelets are acute-phase reactants; therefore, platelet counts increase in response to various stimuli, including systemic infections, inflammatory conditions, bleeding, and tumors. [1, 2, 3] This phenomenon is called reactive...
https://emedicine.medscape.com/article/206811-overview
Aug 10th, 2022 - Practice Essentials Platelets are acute-phase reactants; therefore, platelet counts increase in response to various stimuli, including systemic infections, inflammatory conditions, bleeding, and tumors. [1, 2, 3] This phenomenon is called reactive...
https://emedicine.medscape.com/article/206811-print
Aug 10th, 2022 - Practice Essentials Platelets are acute-phase reactants; therefore, platelet counts increase in response to various stimuli, including systemic infections, inflammatory conditions, bleeding, and tumors.[1, 2, 3] This phenomenon is called reactive ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202899
PloS One; Liisborg C, Skov V et. al.
Jun 17th, 2022 - Peripheral T cell CXCR3 expression has been found uniquely lower in patients having neovascular age-related macular degeneration (nAMD) than in healthy individuals. The CXCR3-axis has been shown to have angiostatic and antifibrotic properties. We ...
Clinicaltrials.gov 6 results
https://clinicaltrials.gov/ct2/show/NCT02098161
Jun 1st, 2022 - PRIMARY OBJECTIVES: I. To determine the efficacy of LCL161 as therapy for primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis (MF) and post-essential thrombocytosis (ET) MF. II. To determine the objective response which is defin...
https://clinicaltrials.gov/ct2/show/NCT03869476
Sep 12th, 2019 - The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefib...
https://clinicaltrials.gov/ct2/show/NCT04054245
Aug 13th, 2019 - PRIMARY OBJECTIVES: I. To determine the efficacy of LOXL2 inhibitor PAT-1251 (PAT-1251) as therapy for primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis (MF), and post-essential thrombocytosis (ET) MF. II. To determine the obj...
https://clinicaltrials.gov/ct2/show/NCT02862366
Oct 31st, 2018 - Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have a higher risk of arterial or deep-vein thrombosis. This is re...
https://clinicaltrials.gov/ct2/show/NCT00586651
Oct 8th, 2015 - This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment at a dosage of 80 mg bid for 18 weeks (126 days) in patients with Polycythemia Vera (PV) who have abnormal baseline neut...
News 13 results
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-selinexor-for-myelofibrosis
Nov 1st, 2022 - The European Commission (EC) has granted an orphan drug designation to selinexor (Xpovio) for the treatment of patients with myelofibrosis.1 Selinexor, a first-in-class, oral XPO1 inhibitor, previously received an orphan drug designation for th...
https://www.onclive.com/view/bomedemstat-demonstrates-early-promise-in-advanced-myelofibrosis
Jul 26th, 2022 - Single-agent bomedemstat (IMG-7289) was found to improve symptom scores, bone marrow fibrosis, spleen volumes, and anemia in patients with advanced myelofibrosis, according to findings from the phase 1/2 IMG-7289-CTP-102 trial (NCT03136185) presen...
https://www.onclive.com/view/addressing-the-challenges-in-diagnosing-mf
May 18th, 2022 - Transcript: Pankit Vachhani, MD: There are a few challenges to the diagnosis of myelofibrosis worth mentioning. One is the presentation to a clinician. Many patients who have some symptoms tend to ignore those or blame it on other causes. There c...
https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera
May 11th, 2022 - Transcript: Pankit Vachhani, MD: Polycythemia vera is diagnosed at a median age of roughly about 60 years. In most patients, it is actually diagnosed in an incidental fashion. Someone goes to their primary care physician or some other physician f...
https://www.onclive.com/view/ong_5qs_with_charles_morris
Mar 15th, 2022 - 1 Why are self-survival and self-renewing pathways such promising areas of discovery at this time for Cephalon? If we can understand the methods and the pathways by which cells are able to either prolong their survival or sustain their own prolif...